Trametinib enhances ATRA-induced differentiation in AML cells

References

• Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49–139.
   PubMed Web of Science ®Google Scholar
• Cook SJ, Aziz N, McMahon M. The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol. 1999;19(1):330–341.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567–572.
   PubMed Web of Science ®Google Scholar
• Ni X, Hu G, Cai X. The success and the challenge of all-trans retinoic acid in the treatment of cancer. Crit Rev Food Sci Nutr. 2019;59(Suppl. 1):S71–S80.
   PubMed Web of Science ®Google Scholar
• Congleton J, MacDonald R, Yen A. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells. Leukemia. 2012;26(6):1180–1188.
   PubMed Web of Science ®Google Scholar
• Kropf PL, Wang L, Zang Y, et al. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia. 2010;24(3):663–665.
   PubMed Web of Science ®Google Scholar
• Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia. 2002;16(4):683–692.
   PubMed Web of Science ®Google Scholar
• Miranda MB, Xu H, Torchia JA, et al. Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway. Leuk Res. 2005;29(11):1293–1306.
   PubMed Web of Science ®Google Scholar
• Weng XQ, Sheng Y, Ge DZ, et al. RAF-1/MEK/ERK pathway regulates ATRA-induced differentiation in acute promyelocytic leukemia cells through C/EBPβ, C/EBPε and PU.1. Leuk Res. 2016;45:68–74.
   PubMed Web of Science ®Google Scholar
• Yen A, Roberson MS, Varvayanis S, et al. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res. 1998;58(14):3163–3172.
   PubMed Web of Science ®Google Scholar
• Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108(6):851–859.
   PubMed Web of Science ®Google Scholar
• Milella M, Konopleva M, Precupanu CM, et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007;109(5):2121–2129.
   PubMed Web of Science ®Google Scholar
• Caunt CJ, Sale MJ, Smith PD, et al. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15(10):577–592.
   PubMed Web of Science ®Google Scholar
• Hoffner B, Benchich K. Trametinib: a targeted therapy in metastatic melanoma. J Adv Pract Oncol. 2018;9(7):741–745.
   PubMedGoogle Scholar
• Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs. 2018;27(1):17–30.
   PubMed Web of Science ®Google Scholar
• Burgess MR, Hwang E, Firestone AJ, et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014;124(26):3947–3955.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Popplewell L, Boyiadzis M, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122(12):1871–1879.
   PubMed Web of Science ®Google Scholar
• Liang C, Ding M, Weng XQ, et al. Combination of enzastaurin and ATRA exerts dose-dependent dual effects on ATRA-resistant acute promyelocytic leukemia cells. Am J Cancer Res. 2019;9(5):906–926.
   PubMed Web of Science ®Google Scholar
• Bertagnolo V, Neri LM, Marchisio M, et al. Phosphoinositide 3-kinase activity is essential for all-trans-retinoic acid-induced granulocytic differentiation of HL-60 cells. Cancer Res. 1999;59(3):542–546.
   PubMed Web of Science ®Google Scholar
• Hevehan DL, Miller WM, Papoutsakis ET. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood. 2002;99(5):1627–1637.
   PubMed Web of Science ®Google Scholar
• Hillmer EJ, Zhang H, Li HS, et al. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016;31:1–15.
   PubMed Web of Science ®Google Scholar
• Yamada O, Ozaki K, Nakatake M, et al. Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells. Histochem Cell Biol. 2010;134(6):555–563.
   PubMed Web of Science ®Google Scholar
• Huang YM, Zheng Y, Li JG, et al. Lentivirus-mediated RNA interference targeting FAMLF-1 inhibits cell growth and enhances cell differentiation of acute myeloid leukemia partially differentiated cells via inhibition of AKT and c-MYC. Oncotarget. 2017;8(60):101372–101382.
   PubMedGoogle Scholar
• Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381–405.
   PubMed Web of Science ®Google Scholar
• Xu Y, Fang SJ, Zhu LJ, et al. DNA-PKcs-SIN1 complexation mediates low-dose X-ray irradiation (LDI)-induced Akt activation and osteoblast differentiation. Biochem Biophys Res Commun. 2014;453(3):362–367.
   PubMed Web of Science ®Google Scholar
• Cleveland-Donovan K, Maile LA, Tsiaras WG, et al. IGF-I activation of the AKT pathway is impaired in visceral but not subcutaneous preadipocytes from obese subjects. Endocrinology. 2010;151(8):3752–3763.
   PubMed Web of Science ®Google Scholar
• Yao Y, Suraokar M, Darnay BG, et al. BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal. 2013;6(257):ra2.
   PubMed Web of Science ®Google Scholar
• Hotokezaka H, Sakai E, Kanaoka K, et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem. 2002;277(49):47366–47372.
   PubMed Web of Science ®Google Scholar
• Wang X, Studzinski GP. Inhibition of p38MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. J Cell Biochem. 2001;82(1):68–77.
   PubMed Web of Science ®Google Scholar
• Zhang JX, Zhuang WJ, Poon KH, et al. Induction of HL-60 cell differentiation by the p38 mitogen-activated protein kinase inhibitor SB203580 is mediated through the extracellular signal-regulated kinase signaling pathway. Anticancer Drugs. 2003;14(1):31–38.
   PubMed Web of Science ®Google Scholar
• Kalmes A, Deou J, Clowes AW, et al. Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor, SB203580. FEBS Lett. 1999;444(1):71–74.
   PubMed Web of Science ®Google Scholar
• Guanizo AC, Fernando CD, Garama DJ, et al. STAT3: a multifaceted oncoprotein. Growth Factors. 2018;36(1–2):1–14.
   PubMed Web of Science ®Google Scholar